Gilead's Descovy HIV Regimen Gets FDA Nod For Label Expansion
Zacks Investment Research | Oct 03, 2019 10:45PM ET
Gilead Sciences, Inc. (NASDAQ:GILD) announced that the FDA approved a label expansion of HIV treatment Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF) as a prevention option.
The agency approved the treatment for a pre-exposure prophylaxis (PrEP) indication. Descovy for PrEP is indicated to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg, who are HIV-negative and at-risk for sexually acquired HIV, excluding individuals at-risk from receptive vaginal sex.
The FDA approved Gilead’s supplemental New Drug Application (sNDA) for Descovy under a Priority Review designation.
The regimen was approved in the United States in 2016 for the treatment of HIV-1 infection in combination with other antiretroviral agents.
Importantly, Descovy for PrEP indication provides a new HIV prevention option that matches Gilead’s other HIV drug Truvada’s high efficacy with statistically significant improvements in renal and bone safety. We note that bone injuries and renal damages have been associated with some HIV treatments and hence these are important considerations as people at risk increasingly use PrEP for longer periods.
The approval was based on encouraging data from the multi-year global phase III registrational study, DISCOVER, wherein Descovy demonstrated non-inferior efficacy and an improved bone and renal safety profile compared with Truvada in people at risk of sexually acquired HIV Infection.
However, the regimen carries a boxed warning in its U.S. product label regarding the risk of post-treatment acute exacerbation of hepatitis B. The label will also include a boxed warning regarding the risk of drug resistance with PrEP use in undiagnosed early HIV-1 infection.
The label expansion will strengthen Gilead’s industry-leading HIV portfolio. We note that the company has shifted focus to the HIV business lately as its HCV franchise continues to dwindle.
Gilead’s stock has lost 0.5% in the year so far compared with the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.